Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers

Published:2020-11-20 Issue:4 Volume:87 Page:1824-1838
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Litzenburger Tobias¹,Steffgen Jürgen²,Benediktus Ewald¹,Müller Fabian¹,Schultz Armin³,Klein Elliott⁴,Ramanujam Meera⁴,Harcken Christian⁴,Gupta Alpana⁴,Wu Jing⁴,Wiebe Sabrina¹,Li Xiujiang⁴,Flack Mary⁴,Padula Steven J.⁵,Visvanathan Sudha⁴,Hünnemeyer Andreas¹,Hui Jianan⁴

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

2. Boehringer Ingelheim International GmbH Biberach Germany

3. CRS Clinical Research Services Mannheim GmbH Mannheim Germany

4. Boehringer Ingelheim Pharmaceuticals Ridgefield CT USA

5. Boehringer Ingelheim International GmbH Ingelheim Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology